For SGLT2 inhibitor users, the cumulative incidence of treatment discontinuation was 27.9% (95% CI 27.6, 28.1) at 1 year and 45.9% (95% CI 45.5, 46.2) at 3 years, when using a grace period of 90 days
Improved Skin Health: Helps to inhibit melanin production, leading to a brighter, more even skin tone and a reduction in hyperpigmentation
Store in a cool dry place and keep out of reach of children
Monitoring schedules vary, but regular follow-up appointments are commonly recommended throughout treatment
Decreased mortality, anti-inflammatory properties and neuroprotective effects can be beneficial in chronic substance use which is associated with neuroinflammation and oxidative stress
Fifth, the weekly higher dose format of 2.4 mg semaglutide (marketed as Wegovy) was approved for weight management, and the lower dose format of 0.51 mg semaglutide (marketed as Ozempic) was approved for treating T2DM)